Savior Lifetec Corporation (TPEX:4167)

Market Cap	6.50B +0.4%
Revenue (ttm)	1.17B -4.1%
Net Income	241.59M -51.4%
EPS	0.77 -50.4%
Shares Out	310.44M
PE Ratio	27.06
Forward PE	n/a
Dividend	0.81 (3.85%)
Ex-Dividend Date	Jul 14, 2025

Volume	921,770
Open	21.15
Previous Close	20.90
Day's Range	20.80 - 21.15
52-Week Range	16.45 - 22.60
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Savior Lifetec

Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is head...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2025, Savior Lifetec's revenue was 1.20 billion, a decrease of -1.28% compared to the previous year's 1.22 billion. Earnings were 537.45 million, an increase of 194.69%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 9, 2026

Data Sources Report a data error